Skip to main content

A phase 1/2 study of KO-539, a menin-MLL(KMT2A) inhibitor, in patients with AML


Kura Oncology


TAP Partner

Project Term: December 22, 2014 - TBD

Starting in July 2010, LLS TAP supported a promising University of Michigan research project led by Jolanta Grembecka, PhD, to develop new treatments for patients with a rare and lethal subtype of leukemia. Through TAP, LLS engaged chemists to improve the properties that produced lead compounds that exhibited potent anti-leukemic activity. In 2014, LLS introduced Kura Oncology to the project that ultimately led to Kura Oncology completing a licensing agreement with the University of Michigan to continue to develop these molecules. KO-539 is a potent and selective menin inhibitor that is currently in a Phase 1/2 clinical trial (KOMET-001) and targeting patients with relapsed/refractory acute myeloid leukemia, including patients with NPM1 mutations or KMT2A rearrangements.

Lay Abstract

For additional information, please visit

Therapy Acceleration Program
To All Projects